Loading clinical trials...
Loading clinical trials...
A Randomized, Observer-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Immunogenicity of the Purified Inactivated Zika Virus Vaccine (PIZV) Administered on Days 1 and 29 in Healthy Participants Aged 18 to 49 Years in the US
Conditions
Interventions
Purified Inactivated Zika Virus Vaccine (PIZV)
Placebo
Locations
5
United States
CenExel Research Centers of America
Oakland Park, Florida, United States
Velocity Clinical Research, Boise
Meridian, Idaho, United States
AMR East Wichita, Formerly Heartland Associates East Wichita, an AMR company
Wichita, Kansas, United States
AMR Lexington, Formerly Central Kentucky Research Associates, an AMR company
Lexington, Kentucky, United States
Alliance for Multispecialty Research, LLC
Kansas City, Missouri, United States
Start Date
January 2, 2024
Primary Completion Date
July 5, 2024
Completion Date
July 5, 2024
Last Updated
March 13, 2024
NCT07310264
NCT06342713
NCT07472361
NCT06823947
NCT06649110
NCT07240675
Lead Sponsor
Takeda
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions